Replies to post #379479 on Amarin Corp Plc (AMRN)

[Whalatane]

Zip. EPA / Vascepa will never equal sales of Statins in our life time

EPA / Vazkepa will only be reimbursed IMHO for secondary prevention in the EU /UK …. With patient co pays hopefully around 10 Euros a month

The price negotiated with the various countries health dept …. Doesn’t matter if it’s AG or Brand . If the brand price is to high to get secondary prevention coverage …. lower the price of the brand … as long as AMRN can still profit from it

We have exclusivity. We don’t need an AG in the UK or EU .
JMO
Kiwi

[L0tsaluck2000]

States that require that a generic must be dispensed over a brand when the generic does not have authorization for that indication should be sued. Why hasn't this happened?